PMID- 29391811
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Safety and efficacy of transarterial chemoembolization with degradable starch 
      microspheres (DSM-TACE) in the treatment of secondary liver malignancies.
PG  - 345-350
LID - 10.2147/OTT.S147852 [doi]
AB  - PURPOSE: To evaluate the safety and efficacy of degradable starch microspheres 
      (DSM) as embolic agents in transarterial chemoembolization (TACE) in the 
      treatment of secondary liver metastases. METHODS: This was a national, 
      multicenter observational study. Primary endpoints were safety and treatment 
      response according to Modified Response Evaluation Criteria in Solid Tumors 
      (mRECIST) criteria. RESULTS: A total of 77 DSM-TACE procedures were performed in 
      20 patients. Minor immediate adverse events (AEs) were epigastric pain with an 
      incidence of 45.5% (35/77), and nausea and vomiting at an incidence of 23.4% 
      (18/77). Delayed minor AEs were epigastric pain in 13/77 (16.9%) treatments and 
      nausea and vomiting in 10 (13.0%) treatments. No severe AEs were documented. 
      Therapeutic efficacy of DSM-TACE procedures according to mRECIST was as follows: 
      complete response 0/77, partial response 17/77, stable disease 33/77 and 
      progressive disease 6/77, no data was available for 21/77 treatments. Overall, 
      objective response was achieved in 8 of 20 patients (40.0%). CONCLUSION: DSM as 
      embolic agent for TACE is safe in the treatment of liver metastases. An objective 
      response in 40.0% of patients and disease control in 64.9% of procedures was 
      achieved, and this should lead to further evaluation of DSM-TACE as treatment 
      option for nonresectable liver metastases.
FAU - Schicho, Andreas
AU  - Schicho A
AD  - Department of Radiology, University Hospital Regensburg, Regensburg.
FAU - Pereira, Philippe L
AU  - Pereira PL
AD  - Department of Radiology, Minimal-invasive Therapies and Nuclear Medicine, SLK 
      Kliniken Heilbronn, Heilbronn, Germany.
FAU - Michalik, Katharina
AU  - Michalik K
AD  - Department of Radiology, University Hospital Regensburg, Regensburg.
FAU - Beyer, Lukas P
AU  - Beyer LP
AD  - Department of Radiology, University Hospital Regensburg, Regensburg.
FAU - Stroszczynski, Christian
AU  - Stroszczynski C
AD  - Department of Radiology, University Hospital Regensburg, Regensburg.
FAU - Wiggermann, Philipp
AU  - Wiggermann P
AD  - Department of Radiology, University Hospital Regensburg, Regensburg.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5769599
OTO - NOTNLM
OT  - DSM
OT  - TACE
OT  - efficacy
OT  - metastases
OT  - safety
OT  - secondary malignancies
COIS- Disclosure Philippe L Pereira in the last 3 years has received speaker's 
      honoraria and grants, has helped organize symposia, and is on the advisory board 
      or acting as a consultant for: Bayer Global and Bayer Germany, Biocompatibles and 
      BTG, Celonova (Boston Scientific), Cook Medical, Pharmacept, SIRTEX, Terumo. 
      Christian Stroszczynski and Philipp Wiggermann received financial support from 
      PharmaCept GmbH for the present study. The authors report no other conflicts of 
      interest in this work.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/03 06:01
PMCR- 2018/01/12
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/03 06:01 [medline]
PHST- 2018/01/12 00:00 [pmc-release]
AID - ott-11-345 [pii]
AID - 10.2147/OTT.S147852 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Jan 12;11:345-350. doi: 10.2147/OTT.S147852. eCollection 
      2018.